The study is being conducted at Basel in Switzerland under a clinical trial application approved by SwissMedic, the regulatory authority of the country. The study is expected to be completed by December 2008. The company targets to launch the molecule in 2012.
According to Suven Chief Executive Officer Venkat Jasti, SUVN-502 is the first NCE (new chemical entity) of the company to enter the clinical trials from a pipeline of six NCEs. The CNS (central nervous system) market worldwide is of the order $20 billion.
Suven's Vice President (Discovery Research) Ramakrishna Niyogi stated that the company was also in discussions for potential licensing partners for the compound. Timing of the licensing would depend on the deal terms and ability to get co-promotion rights in some of the regulated markets, he added.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app